Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01018173 · ClinicalTrials.gov registry record · Phase 3
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,118
- Enrollment target
NCT01018173: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT01018173 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 2,118 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (174% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01018173, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,118 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled parallel arm study will assess efficacy and safety and the effects of taspoglutide on cardiovascular events in patients with inadequately controlled type 2 diabetes mellitus and established cardiovascular disease. Patients will be randomized to receive either taspoglutide subcutaneously (sc) 10mg weekly for 4 weeks followed by 20mg sc weekly, or weekly sc placebo, in addition to background anti-hyperglycemic medication and standard of care treatment for cardiovascular disease. Anticipated time on study treatment is up to 2 years. Target sample size is 2000 patients.
Interventions
- DRUG placebo
- DRUG taspoglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,118 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
What the finished NCT01018173 record still lists
NCT01018173 is an interventional study that assigns participants to a tested intervention. Its 2,118 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (174% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01018173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01018173 about?
NCT01018173 is a clinical study titled "A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease". This randomized, double-blind, placebo-controlled parallel arm study will assess efficacy and safety and the effects of taspoglutide on cardiovascular events in patients with inadequately controlled type 2 diabetes mellitus and established cardiovascular disease. Patients will be randomized to recei...
What is the current status of trial NCT01018173?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,118 participants. The study started on 2010-01. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01018173?
The interventions under investigation include: placebo (DRUG), taspoglutide (DRUG).
Who is sponsoring clinical trial NCT01018173?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01018173's enrollment target sits among peer trials
2,118 98th of 2000 higher than 1,903 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05916430 · 2,120 participants
Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement
- NCT05681624 · 2,124 participants · NA
Maternal Oxygen Supplementation for Intrauterine Resuscitation
- NCT07431281 · 2,130 participants · Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- NCT05967273 · 2,106 participants · NA
CirrhosisRx CDS System
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia